Kyocera Announces December 15 ReBOSSIS Webinar

December 7, 2020 – ReBOSSIS®️ from Kyocera Medical Technologies, Inc. is the only biosynthetic bone scaffold with electrospun microfiber construction. This process results in a material with excellent handleability, similar to cotton. ReBOSSIS is hydrophilic, meaning it absorbs and retains bioactive fluids, enhancing osteoinductive potential. With microporous fibers that are a composite of β-TCP, CaCO3, silicon, and PLGA, ReBOSSIS has been proven to support cell activation, retention, and proliferation.*

We are excited to share these opportunities to learn about this unique biologics offering:

Attend a webinar.

Tuesday, December 15, 2020, Dr. Boyle Cheng will present the physical characteristics of the ReBOSSIS technology, contrasting it with other biologics products. You’ll learn how this fibrous scaffold supports rapid proliferation of osteoblasts as evidenced by ALP expression, ECM formation, and mineralization.

Dr. Boyle Cheng is a Professor in the Department of Neurosurgery at Drexel University, Allegheny General Hospital, and Director of Research at the Neuroscience Institute at Allegheny Health Network.
Sign up today for this free event hosted by Becker’s Hospital Review!

Visit the ReBOSSIS website.

Find out more about this technology by watching an instructional video and downloading a white paper, brochure, and case studies…all available on the ReBOSSIS website.

  • Based on results of 2017 tests carried out at the Cleveland Clinic Lerner Research Institute. Data on file with Kyocera Medical Technologies, Inc.